ストックスクリーナーアプリを入手
107.51
2.47%
-2.72
アフターアワーズ：
107.75
0.24
+0.22%
前日終値:
$110.23
開ける：
$109.69
24時間の取引高:
11.68M
Relative Volume:
1.63
時価総額：
$133.89B
収益：
$28.75B
当期純損益:
$480.00M
株価収益率:
290.57
EPS:
0.37
ネットキャッシュフロー:
$10.31B
1週間 パフォーマンス:
-5.68%
1か月 パフォーマンス:
-0.13%
6か月 パフォーマンス:
+28.14%
1年 パフォーマンス:
+46.45%
1日の値動き範囲:
$105.80
$109.72
1週間の範囲:
$105.80
$115.47
52週間の値動き範囲:
$62.07
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
107.51 | 133.89B | 28.75B | 480.00M | 10.31B | 0.37 |
|
LLY
Lilly Eli Co
|
837.01 | 751.78B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
212.25 | 374.70B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
79.00 | 350.69B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
162.99 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
94.02 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead stock falls on report of HIV prevention cuts - Yahoo Finance
Gilead Stock Dives On A Devastating Potential Call From HHS - Investor's Business Daily
Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts - Investing.com Canada
Citi maintains Gilead stock Buy rating, $125 target amid HIV funding fears - Investing.com
Gilead Sciences Should Not See Any Impact From HIV-Related Cost Reductions at US Healthcare Department, Truist Says - Marketscreener.com
BMO reiterates Gilead stock with $115 target amid HIV funding concerns - Investing.com India
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies - CSRwire.com
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition - Investing.com
Gilead Sciences Stock Slips on Possible HIV Funding Cut - Schaeffers Research
Why Gilead Sciences (GILD) Is Among the Most Undervalued Biotech Stocks to Invest In - Insider Monkey
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025' - StreetInsider.com
The Trump Administration Wants to Cut Funding for HIV Prevention. Why Gilead Stock Is Falling. - Barron's
Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention - Markets Insider
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides - Benzinga
Gilead Stock (NYSE:GILD) Slumps on HIV Funding Cuts Report - TipRanks
Gilead slides as Trump administration puts HIV prevention funds under review - TradingView
Gilead Stock Falls on Report U.S. Could Slash HIV-Prevention Budget - The Wall Street Journal
Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts - Value the Markets
Gilead, GSK could be impacted by potential HHS HIV prevention cuts - Seeking Alpha
Gilead Sciences CFO Andrew Dickinson sells $276,325 in stock - Investing.com
After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more - Investing.com
Gilead Sciences stock falls on potential HIV funding cuts By Investing.com - Investing.com Australia
Gilead Sciences stock falls on potential HIV funding cuts - Investing.com
Unpacking the Latest Options Trading Trends in Gilead Sciences - Benzinga
Gilead Sciences (GILD): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Coronavirus: La Commission européenne signe un accord avec Gilead sur le remdesivir - Reuters
Is Gilead Sciences, Inc. (GILD) a Best Biotech Stock According to Billionaires? - Yahoo Finance
7 Most Undervalued Biotech Stocks To Invest In - Insider Monkey
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell? - Yahoo Finance
Gilead SciencesWomen's History Month Celebrated With Its Team - CSRwire.com
Is Gilead Sciences, Inc. (GILD) The Most Undervalued NASDAQ Stock To Buy According To Hedge Funds? - Insider Monkey
Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally - Seeking Alpha
Gilead's accounting chief hits the exit—Chutes & Ladders - Fierce Biotech
Gilead Sciences: A rare Nasdaq gem with consistent returns across time horizons - The Financial Express
Merck’s HIV Combo Shows Non-Inferiority To Gilead’s Biktarvy - Citeline News & Insights
Is Gilead Sciences Gaining or Losing Market Support? - Benzinga
Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds - Insider Monkey
May 2nd Options Now Available For Gilead Sciences (GILD) - Nasdaq
The Global Health Challenge of HIV and Hepatitis B Coinfections - Gilead Sciences
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Gilead Sciences CFO sells $2.1 million in stock - Investing.com
Gilead Pushes PrEP Envelope As ViiV Explores Self-Administered, Long-Acting Drugs - Citeline News & Insights
Gilead Sciences announces executive departure and interim appointment By Investing.com - Investing.com South Africa
Gilead Sciences announces executive departure and interim appointment - Investing.com
Gilead Presents New HIV Treatment And Cure Research Data - AOL
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive - Zacks Investment Research
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
大文字化:
|
ボリューム (24 時間):